# RCBTB2

## Overview
RCBTB2, or RCC1 and BTB domain containing protein 2, is a gene that encodes a protein involved in critical cellular processes, including cell cycle regulation and signal transduction. The protein is characterized by the presence of RCC1-like domains (RLDs) and BTB/POZ domains, which facilitate protein-protein interactions essential for its function in cellular activities (Hadjebi2008The). RCBTB2 is expressed in both the cytoplasm and nucleus, where it plays a role in cell proliferation and differentiation (Hadjebi2008The). It is notably overexpressed in certain cancers, such as medulloblastoma, where it is implicated in the SHH signaling pathway, and is considered a candidate tumor suppressor in prostate cancer (Majewski2008Understanding; Vriend2019Differential). The protein's involvement in these pathways highlights its potential significance in oncogenesis and as a therapeutic target. However, further research is needed to fully elucidate its functions in normal cellular contexts.

## Structure


## Function
RCBTB2 (RCC1 and BTB domain containing protein 2) is involved in several cellular processes, primarily through its role in cell cycle regulation and signal transduction. The protein contains RCC1-like domains (RLDs) and BTB/POZ domains, which facilitate protein-protein interactions, crucial for its function in cellular activities (Hadjebi2008The). RCBTB2 is active in both the cytoplasm and nucleus, where it influences cell proliferation and differentiation (Hadjebi2008The).

In the context of medulloblastoma, particularly the SHH subgroup, RCBTB2 is significantly overexpressed and is thought to regulate chromosome condensation and act as a guanine nucleotide exchange factor. Its expression is positively correlated with BOC, a co-receptor of the SHH pathway, suggesting a role in SHH signaling (Vriend2019Differential). This indicates its potential involvement in regulating cell cycle entry and exit, although its specific function in healthy cells remains to be fully elucidated (Vriend2019Differential).

RCBTB2 has also been implicated as a candidate tumor suppressor in prostate cancer, highlighting its potential role in maintaining genomic stability and preventing carcinogenesis (Majewski2008Understanding). However, detailed functional studies in healthy human cells are limited, and further research is needed to fully understand its biological roles.

## Clinical Significance
The RCBTB2 gene has been implicated in various clinical conditions, particularly in cancer and genetic disorders. In medulloblastoma, specifically the SHH subgroup, RCBTB2 is significantly overexpressed compared to other subtypes and normal cerebellum, suggesting a role in the SHH signaling pathway and potential as a marker for SHH medulloblastomas (Vriend2019Differential). In retinoblastoma, large deletions involving RCBTB2 and neighboring genes have been observed, with affected patients often presenting with learning difficulties and dysmorphic features (Lan2020Spectrum).

RCBTB2 has also been associated with leukemia. In pediatric T-cell acute lymphoblastic leukemia (T-ALL), the RCBTB2::LPAR6 fusion has been identified, indicating a partial loss of the RB1 gene, which is crucial for tumor suppression (Walter2021Clinical; Singh2024Integrated). This fusion is also noted in B-cell acute lymphoblastic leukemia (B-ALL), highlighting its potential role in leukemogenesis.

In liposarcoma, RCBTB2 interacts with COPS4, suggesting a regulatory role in the phosphorylation of proteins like p53 and c-Jun, which are involved in cancer-related pathways (Lee2013Overexpression). These findings underscore the gene's involvement in various malignancies and its potential as a therapeutic target.

## Interactions
RCBTB2 is involved in several protein interactions that suggest its role in cellular processes related to tumorigenesis and cell cycle regulation. It interacts with COPS4 (constitutive photomorphogenic homolog subunit 4), which indicates a potential role in regulating the phosphorylation of key proteins such as p53 and c-Jun, both of which are crucial in cell cycle control and apoptosis (Lee2013Overexpression). 

In the context of medulloblastoma, particularly the SHH subgroup, RCBTB2 expression is elevated and is positively correlated with the SHH co-receptor BOC. This suggests that RCBTB2 may play a role in the SHH signaling pathway, although the specific interactions within this pathway are not fully elucidated (Vriend2019Differential). 

RCBTB2 is part of the RCC1 superfamily, which includes proteins characterized by RCC1-like domains (RLDs) and BTB domains, known for mediating protein-protein interactions. These structural features imply that RCBTB2 may participate in multiprotein complexes, although specific partners are not detailed in the available literature (Hadjebi2008The). 

Overall, while specific interaction partners of RCBTB2 are not comprehensively detailed, its structural domains and expression patterns suggest significant roles in protein interactions and cellular regulatory mechanisms.


## References


[1. (Majewski2008Understanding) Tadeusz Majewski, Sangkyou Lee, Joon Jeong, Dong-Sup Yoon, Andrzej Kram, Mi-Sook Kim, Tomasz Tuziak, Jolanta Bondaruk, Sooyong Lee, Weon-Seo Park, Kuang S Tang, Woonbok Chung, Lanlan Shen, Saira S Ahmed, Dennis A Johnston, H Barton Grossman, Colin P Dinney, Jain-Hua Zhou, R Alan Harris, Carrie Snyder, Slawomir Filipek, Steven A Narod, Patrice Watson, Henry T Lynch, Adi Gazdar, Menashe Bar-Eli, Xifeng F Wu, David J McConkey, Keith Baggerly, Jean-Pierre Issa, William F Benedict, Steven E Scherer, and Bogdan Czerniak. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Laboratory Investigation, 88(7):694–721, July 2008. URL: http://dx.doi.org/10.1038/labinvest.2008.27, doi:10.1038/labinvest.2008.27. This article has 62 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/labinvest.2008.27)

[2. (Walter2021Clinical) Wencke Walter, Rabia Shahswar, Anna Stengel, Manja Meggendorfer, Wolfgang Kern, Torsten Haferlach, and Claudia Haferlach. Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia. BMC Cancer, August 2021. URL: http://dx.doi.org/10.1186/s12885-021-08635-5, doi:10.1186/s12885-021-08635-5. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-021-08635-5)

[3. (Singh2024Integrated) Minu Singh, Pankaj Sharma, Prateek Bhatia, Amita Trehan, Rozy Thakur, and Sreejesh Sreedharanunni. Integrated analysis of transcriptome and genome variations in pediatric t cell acute lymphoblastic leukemia: data from north indian tertiary care center. BMC Cancer, March 2024. URL: http://dx.doi.org/10.1186/s12885-024-12063-6, doi:10.1186/s12885-024-12063-6. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-024-12063-6)

[4. (Hadjebi2008The) Ouadah Hadjebi, Eduard Casas-Terradellas, Francesc R. Garcia-Gonzalo, and Jose Luis Rosa. The rcc1 superfamily: from genes, to function, to disease. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1783(8):1467–1479, August 2008. URL: http://dx.doi.org/10.1016/j.bbamcr.2008.03.015, doi:10.1016/j.bbamcr.2008.03.015. This article has 108 citations.](https://doi.org/10.1016/j.bbamcr.2008.03.015)

[5. (Lee2013Overexpression) D H Lee, S Amanat, C Goff, L M Weiss, J W Said, N B Doan, A Sato-Otsubo, S Ogawa, C Forscher, and H P Koeffler. Overexpression of mir-26a-2 in human liposarcoma is correlated with poor patient survival. Oncogenesis, 2(5):e47–e47, May 2013. URL: http://dx.doi.org/10.1038/oncsis.2013.10, doi:10.1038/oncsis.2013.10. This article has 41 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/oncsis.2013.10)

[6. (Vriend2019Differential) Jerry Vriend and Robert B. Tate. Differential expression of genes for ubiquitin ligases in medulloblastoma subtypes. The Cerebellum, 18(3):469–488, February 2019. URL: http://dx.doi.org/10.1007/s12311-019-1009-y, doi:10.1007/s12311-019-1009-y. This article has 3 citations.](https://doi.org/10.1007/s12311-019-1009-y)

[7. (Lan2020Spectrum) Xiaoping Lan, Wuhen Xu, Xiaojun Tang, Haiyun Ye, Xiaozhen Song, Longlong Lin, Xiang Ren, Guangjun Yu, Hong Zhang, and Shengnan Wu. Spectrum of rb1 germline mutations and clinical features in unrelated chinese patients with retinoblastoma. Frontiers in Genetics, March 2020. URL: http://dx.doi.org/10.3389/fgene.2020.00142, doi:10.3389/fgene.2020.00142. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2020.00142)